According to industry statistics, in the past 10 days (January 3 to January 16), overseas institutions conducted research on 64 listed companies, which are mainly concentrated in household appliances, machinery and equipment, electronics, medicine and biology and other industries, including 8 pharmaceutical and biological companies
.
From the research list, Zhifei Biology has attracted particular attention, and has been surveyed by 36 overseas institutions in the past 10 days
.
The new closing price of the stock on the 16th was 106.
52 yuan, an increase of 21.
28%
during the period.
According to the data, Zhifei Biotech is mainly engaged in the research and development, production and sales
of vaccines and biological products.
At this stage, relying on the three major R&D and production bases in Beijing, Anhui and Chongqing, Zhifei has built nine R&D technology platforms and six product matrices, continuously accelerating the development progress of independent R&D projects and accelerating the pace of
product launch.
In the survey, Zhifei Biotechnology said that 23-valent pneumonia polysaccharide vaccine, diploid rabies vaccine, quadrivalent influenza virus vaccine and other products are expected to be reported or marketed
in the following years.
At the same time, the 15-valent pneumonia conjugate vaccine, bivalent dysentery vaccine and quadrivalent flow brain conjugate vaccine, which are currently undergoing phase III.
clinical trials, are also progressing satisfactorily
.
The company will actively promote the progress of the pipeline and accelerate the process
of products from R&D to market.
According to the third quarter report of 2022, the main revenue of Zhifei Biotech was 27.
823 billion yuan, a year-on-year increase of 27.
46%; the net profit attributable to the parent was 5.
607 billion yuan, down 33.
28% from the same period last year; Non-net profit was 5.
59 billion yuan, down 33.
59%
from the same period last year.
It was followed by Haier Biotechnology, which received a total of 16 overseas institutions
.
The stock closed at 71.
47 yuan on the 16th, up 12.
91%
during the period.
According to the data, Haier Biotech is mainly engaged in the research and development, production and sales of biomedical cryogenic storage equipment, and the company independently develops and produces basic laboratory instruments and equipment
such as biological safety cabinets, clean workbenches and carbon dioxide incubators.
A few days ago, some institutions pointed out that the highlight of Haier Biotech is that based on the research and development results of IoT vaccine storage devices, the company has launched IoT smart vaccination solutions, including cold chain room vaccine refrigerators, vaccination table vaccine refrigerators and other products, as well as VIMS vaccination management system, to implement digital and intelligent transformation for vaccination sites; At the same time, the company's nucleic acid sampling workstation has been landed in Beijing, Shanghai, Shenzhen, Chongqing and other cities; In addition, the company is breaking through biomedical cryogenic storage technology to achieve import substitution
.
In terms of news, recently, Haier Biotech has two M&A projects that have attracted much attention, one is the acquisition of Shenzhen Jinweixin Information Technology Co.
, Ltd.
, a leading enterprise in the domestic immunization planning information industry, which will help the company improve the one-stop scene experience of the whole process of "hardware + platform + service" vaccines and enhance the comprehensive competitiveness of medical innovation digital scene solutions
.
The second is the acquisition of Suzhou Kangsheng, and Haier Biotech will further layout the field of
laboratory disposable plastic consumables.
It is reported that in the future, while continuously deepening smart laboratory services, the company will continue to extend to application scenarios such as biopharmaceuticals and IVD diagnostics, and realize the upgrade
from equipment to platform to service.
In the first three quarters of 2022, Haier Biotech achieved revenue of 2.
075 billion yuan, a year-on-year increase of 36.
52%, and a net profit of 461 million yuan, a year-on-year decrease of 33.
91%.
In addition to the above two pharmaceutical companies, in the past 10 days, pharmaceutical companies such as Jingxin Pharmaceutical, Haixiang Pharmaceutical, Baicheng Pharmaceutical, Boyaa Biotechnology, Dirui Medical, and China Resources Sanjiu have also been investigated
by overseas institutions.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
